Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation

被引:66
作者
Mangal, Sharad [1 ]
Nie, Haichen [2 ]
Xu, Rongkun [1 ,3 ]
Guo, Rui [1 ]
Cavallaro, Alex [4 ]
Zemlyanov, Dmitry [5 ]
Zhou, Qi [1 ]
机构
[1] Purdue Univ, Coll Pharm, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA
[2] Teva Pharmaceut, 145 Brandywine Pkwy West, Chester, PA 19380 USA
[3] Shenyang Pharmaceut Univ, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
[4] Univ South Australia, Future Ind Inst, Mawson Lakes, SA 5095, Australia
[5] Purdue Univ, Birck Nanotechnol Ctr, 1205 West State St, W Lafayette, IN 47907 USA
基金
美国国家卫生研究院;
关键词
aerosol performance; azithromycin; dissolution; dry powder inhaler; L-leucine; poorly water soluble drug; solubility; spray drying; WATER-SOLUBLE DRUGS; SOLID-STATE PROPERTIES; DRY POWDER INHALER; AMINO-ACIDS; PULMONARY DELIVERY; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; DISPERSION PERFORMANCE; AMORPHOUS STABILIZERS; FORMULATION;
D O I
10.1007/s11095-017-2334-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose Inhalation therapy is popular to treat lower respiratory tract infections. Azithromycin is effective against some bacteria that cause respiratory tract infections; but it has poor water solubility that may limit its efficacy when administrated as inhalation therapy. In this study, dry powder inhaler formulations were developed by co-spray drying azithromycin with L-leucine with a purpose to improve dissolution. Methods The produced powder formulations were characterized regarding particle size, morphology, surface composition and in-vitro aerosolization performance. Effects of L-leucine on the solubility and in-vitro dissolution of azithromycin were also evaluated. Results The spray dried azithromycin alone formulation exhibited a satisfactory aerosol performance with a fine particle fraction (FPF) of 62.5 +/- 4.1%. Addition of L-leucine in the formulation resulted in no significant change in particle morphology and FPF, which can be attributed to enrichment of azithromycin on the surfaces of composite particles. Importantly, compared with the spray-dried amorphous azithromycin alone powder, the co-spray dried powder formulations of azithromycin and L-leucine demonstrated a substantially enhanced in-vitro dissolution rate. Such enhanced dissolution of azithromycin could be attributed to the formation of composite system and the acidic microenvironment around azithromycin molecules created by the dissolution of acidic L-leucine in the co-spray dried powder. Fourier transform infrared spectroscopic data showed intermolecular interactions between azithromycin and L-leucine in the co-spray dried formulations. Conclusions We developed the dry powder formulations with satisfactory aerosol performance and enhanced dissolution for a poorly water soluble weak base, azithromycin, by co-spray drying with an amino acid, L-leucine.
引用
收藏
页数:15
相关论文
共 72 条
  • [2] Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability
    Arora, Sumit
    Haghi, Mehra
    Young, Paul M.
    Kappl, Michael
    Traini, Daniela
    Jain, Sanyog
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (02) : 183 - 193
  • [3] Amorphous azithromycin with improved aqueous solubility and intestinal membrane permeability
    Aucamp, Marique
    Odendaal, Roelf
    Liebenberg, Wilna
    Hamman, Josias
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (07) : 1100 - 1108
  • [4] Application of Spray-drying and Electrospraying/Electospinning for Poorly Water-soluble Drugs: A Particle Engineering Approach
    Bohr, Adam
    Boetker, Johan P.
    Rades, Thomas
    Rantanen, Jukka
    Yang, Mingshi
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (03) : 325 - 348
  • [5] Particles and powders: Tools of innovation for non-invasive drug administration
    Buttini, Francesca
    Colombo, Paolo
    Rossi, Alessandra
    Sonvico, Fabio
    Colombo, Gaia
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 161 (02) : 693 - 702
  • [6] Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients
    Catherinot, Emilie
    Roux, Anne-Laure
    Vibet, Marie-Anne
    Bellis, Gil
    Lemonnier, Lydie
    Le Roux, Evelyne
    Bernede-Bauduin, Claire
    Le Bourgeois, Muriel
    Herrmann, Jean-Louis
    Guillemot, Didier
    Gaillard, Jean-Louis
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (05) : 1101 - 1106
  • [7] Novel alternative methods for the delivery of drugs for the treatment of asthma
    Chan, HK
    Chew, NYK
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (07) : 793 - 805
  • [8] Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol
    Chang, Anne B.
    Grimwood, Keith
    White, Andrew V.
    Maclennan, Carolyn
    Sloots, Theo P.
    Sive, Alan
    McCallum, Gabrielle B.
    Mackay, Ian M.
    Morris, Peter S.
    [J]. TRIALS, 2011, 12
  • [9] Co amorphous systems: A product development perspective
    Chavan, Rahul B.
    Thipparaboina, Rajesh
    Kumar, Dinesh
    Shastri, Nalini R.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 515 (1-2) : 403 - 415
  • [10] Amorphous powders for inhalation drug delivery
    Chen, Lan
    Okuda, Tomoyuki
    Lu, Xiang-Yun
    Chan, Hak-Kim
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2016, 100 : 102 - 115